Company
Peptomyc
Peptomyc uses mini-protein therapeutics to directly inhibit MYC for cancers with abnormal MYC activity.
Also known as PEPTOMYC SL
- Status
- Operatingas of 2026-09-23
- Business model
- B2B
- Founded
- 2014
- Employees
- 15 employeesSource (opens in a new tab)
- Legal name
- PEPTOMYC SL
- peptomyc.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Peptomyc is a spin-off from the Vall d’Hebron Institute of Oncology (VHIO) that is revolutionizing cancer treatment: we are the only company that uses mini-protein therapeutics to directly inhibit MYC – the central engine for cancer proliferation, survival, and resistance to treatment. Doing so, Peptomyc offers a foundational treatment to any cancer patient with abnormal MYC activity, improving patient’ survival and quality of life.
Funding snapshot
- Latest round
- Undisclosed2026-03-24
Funding rounds
- Equity Financing
- 2026-03-24
- Grant
- 2024-04-30
Products
- Other
- OMO-103
Loading relationship preview